85174
document
MR imaging of pituitary region lesions with gadodiamide injection . Twelve patients with known or suspected pituitary lesions underwent MR imaging with gadodiamide injection at a dose of 0.1 ( n = 5 ) or 0.3 ( n = 7 ) mM/kg . Six of the patients were also studied with 0.1 mM/kg gadopentetate dimeglumine . Consistent with previous reports gadodiamide injection was found to be a safe and effective contrast medium for MR imaging of the pituitary region . No additional diagnostic information was obtained using 0.3 mM/kg gadodiamide injection compared to 0.1 mM/kg gadopentate dimeglumine in the same patients . The high dose ( 0.3 mM/kg ) gadodiamide injection in 7 patients did not shorten the T2 value sufficiently to overwhelm the T1 shortening and leave pathologic lesions hypointense compared to precontrast studies . With the comparable relaxivities of gadodiamide injection and gadopentetate dimeglumine , similarities in results have to be expected when using these media for MR image enhancement .
85175
Intervention_Pharmacological
gadodiamide
85176
Intervention_Physical
MR imaging
85177
Intervention_Pharmacological
gadodiamide injection
85178
Intervention_Pharmacological
0.1 mM/kg gadopentetate dimeglumine
85179
Intervention_Pharmacological
gadodiamide
85180
Intervention_Pharmacological
gadodiamide
85181
Intervention_Pharmacological
gadodiamide
85182
Intervention_Pharmacological
gadodiamide
85183
Intervention_Pharmacological
gadopentetate dimeglumine
85184
Outcome_Other
safe and effective
85185
Outcome_Physical
shorten the T2 value sufficiently
85186
Outcome_Physical
T1 shortening
85187
Outcome_Other
and
85188
Outcome_Physical
leave pathologic lesions hypointense